VOLT

Levolta Pharmaceuticals is a clinical-stage biotechnology company focused on reformulating existing late-stage therapeutic products to improve their efficacy, safety profiles, and commercial potential. The company's lead program, VOLT01, is a novel derivative of zoledronic acid currently in Phase 3 registration trials for the treatment of knee osteoarthritis. Its second major candidate, VOLT02, is a water-soluble conjugated progesterone being developed for traumatic brain injury (TBI). By utilizing the 505(b)(2) regulatory pathway, Levolta aims to significantly reduce drug development timelines and costs while addressing significant unmet needs in musculoskeletal and neurological disorders.